we completed patient enrollment in a phase 2 , randomized , double-blind , placebo-controlled clinical trial evaluating retaspimycin hcl in combination with docetaxel , a chemotherapy , compared to placebo and docetaxel in 226 patients with second- or third-line non-small cell lung cancer ( nsclc ) , who are naive to docetaxel treatment and have a history of heavy smoking . we stratified patients in our phase 2 trial by squamous cell carcinoma and adenocarcinoma based on results from our phase 1b trial in which we observed partial responses in patients with squamous cell carcinoma . in addition , we are prospectively evaluating a novel biomarker that we believe may be predictive of response . we expect to report topline overall survival data from this trial in the first half of 2013. we are also enrolling patients in a phase 1b/2 trial to explore the safety and efficacy of retaspimycin hcl in combination with everolimus , an inhibitor of the mammalian target of rapamycin ( mtor ) , pathway , in nsclc patients with a kras gene mutation . the objective of this phase 1b/2 trial is to determine the recommended dose for the combination treatment and to evaluate the safety and clinical activity of retaspimycin hcl in combination with everolimus . we expect to provide an update from this phase 1b/2 trial in the first half of 2013. in addition to our clinical stage programs , we have multiple innovative projects in earlier stages of development . through our internal discovery efforts , we also discovered ipi-940 , a novel , orally available inhibitor of faah . it is believed that inhibition of faah may enable the body to bolster its own analgesic and anti-inflammatory response , and may have applicability in a broad range of painful or inflammatory conditions . we are currently seeking potential partnering opportunities for our faah program . in june 2012 , we voluntarily stopped all company-sponsored clinical trials of saridegib , our lead hedgehog pathway inhibitor . strategic alliances millennium in july 2010 , we entered into a development and license agreement with intellikine , inc. , or intellikine , under which we obtained rights to discover , develop and commercialize pharmaceutical products targeting the delta and or gamma isoforms of pi3k , including ipi-145 . we paid intellikine a $ 13.5 million up-front license fee . the entirety of this fee was included as research and development expense in the year ended december 31 , 2010 , although $ 8.5 million of this fee was paid in january 2011. during the second half of 2011 , we paid intellikine $ 4.0 million in milestone payments associated with the initiation of two phase 1 studies of ipi-145 , which we recorded as research and development expense . in january 2012 , intellikine was acquired by takeda pharmaceutical company limited , or takeda , acting through its millennium business unit . we refer to our pi3k program licensor as millennium . in december 2012 , we amended and restated our development and license agreement with millennium . under the original agreement , we obtained worldwide development and commercialization rights to millennium 's portfolio of inhibitors of the delta and or gamma isoforms of pi3k for all indications , and we conducted a collaborative research program with millennium to identify compounds directed to pi3k-delta and or pi3k-gamma which meet certain selectivity criteria , with such research collaboration under the original agreement set to expire in july 2013. also under the original agreement , neither we nor millennium were permitted to research , develop or commercialize products directed pi3k-delta and or pi3k-gamma which meet certain selectivity criteria , other than the compounds subject to the collaboration , except that millennium was permitted to research , develop or commercialize such products that it was researching , developing or commercializing on its own or with a third party prior to its acquisition of intellikine . 45 under the terms of the amended and restated agreement , we retained our worldwide development and commercialization rights for products arising from the agreement for all therapeutic indications . we and millennium will no longer conduct the collaborative research program and the restrictions on each party 's ability to research , develop and commercialize products directed to the delta and or gamma isoforms of pi3k that meet certain selectivity criteria have terminated , subject , in the case of millennium , to the exclusive licenses granted to us under the amended and restated agreement . additionally , under the amended and restated agreement , millennium waived the option it had under the original agreement to convert , upon payment of an option fee , its royalty interest in u.s. sales of pi3k products and its right to receive certain milestone payments with respect to such products into the right to share in 50 % of profits and losses on u.s. development and commercialization of those pi3k products for which the first phase 2 clinical trial , as defined in the original agreement , was conducted in an oncology indication , and to participate in up to 30 % of the detailing effort for these products in the united states . in consideration of such waiver we have agreed to pay to millennium $ 15 million payable in installments . we have paid $ 1.7 million of the $ 15 million during the year ended december 31 , 2012. additionally , under the amended and restated agreement we have paid millennium a $ 5 million milestone payment associated with the initiation of our phase 2a clinical trial of ipi-145 in patients with mild , allergic asthma . under the terms of the original agreement , the initiation of the phase 2a trial in asthma would not have required a milestone payment . story_separator_special_tag financial overview revenue all of our revenue to date has been derived from license fees , the reimbursement of research and development costs , contract service revenue and milestone payments received from our collaboration partners . license fees were recognized as revenue ratably over the expected research and development period under our arrangement with mundipharma and purdue . because our agreements with mundipharma and purdue also provided for funding for our research and development efforts , we recognized this cost reimbursement as revenue in the period earned in proportion to our forecasted total expenses as compared to the total research funding budget for the year . in the future , we may generate revenue from a combination of product sales , research and development support services and milestone payments in connection with strategic relationships , and royalties resulting from the sales of products developed under licenses of our intellectual property . we expect that any potential future revenue we generate will fluctuate from year to year as a result of the timing and amount of license fees , research and development reimbursement , milestone and other payments earned under our collaborative or strategic relationships , and the amount and timing of payments that we earn upon the sale of our products , to the extent any are successfully commercialized . research and development expense we are a drug discovery and development company . our research and development expense primarily consists of the following : compensation of personnel associated with research activities ; clinical testing costs , including payments made to contract research organizations ; costs of purchasing laboratory supplies and materials ; costs of manufacturing product candidates for preclinical testing and clinical studies ; costs associated with the licensing of research and development programs ; preclinical testing costs , including costs of toxicology studies ; fees paid to external consultants ; fees paid to professional service providers for independent monitoring and analysis of our clinical trials ; costs for collaboration partners to perform research activities , including development milestones for which a payment is due when achieved ; depreciation of equipment ; and allocated costs of facilities . 50 general and administrative expense general and administrative expense primarily consists of compensation of personnel in executive , finance , accounting , legal , information technology infrastructure , corporate communications , corporate development , human resources and commercial functions . other costs include facilities costs not otherwise included in research and development expense , and professional fees for legal and accounting services . general and administrative expense also consists of the costs of maintaining our intellectual property portfolio . other income and expense interest and investment income typically consists of interest earned on cash , cash equivalents and available-for-sale securities , net of interest expense , and amortization of warrants . interest expense included amortization of the loan commitment asset from purdue entities , net , from april 2009 through november 2011 when we drew down the full $ 50 million loan available under the line of credit agreement . interest expense also included accrued interest on the long-term debt , including amortization of the debt discount , through september 7 , 2012 when the debt was extinguished . income from massachusetts tax incentive award represents the pro-rata amount earned for an award we received for headcount growth . critical accounting policies and significant judgments and estimates the following discussion and analysis of our financial condition and results of operations is based on our financial statements , which have been prepared in accordance with accounting principles generally accepted in the united states . the preparation of these financial statements requires us to make judgments , estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes . on an ongoing basis , we evaluate our estimates , including those related to revenue recognition , accrued expenses , and assumptions in the valuation of stock-based compensation . we base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances . actual results could differ from those estimates . differences between actual and estimated results have not been material and are adjusted in the period they become known . we believe that the following accounting policies and estimates are most critical to understanding and evaluating our reported financial results . please refer to note 2 to our consolidated financial statements for a description of our significant accounting policies . revenue recognition to date , all of our revenue has been generated under research collaboration agreements . the terms of these research collaboration agreements may include payment to us of non-refundable , up-front license fees , funding or reimbursement of research and development efforts , milestone payments if specified objectives are achieved , and or royalties on product sales . on january 1 , 2011 , we adopted on a prospective basis a newly issued accounting standard related to multiple-deliverable revenue arrangements . we apply this standard to new revenue arrangements or material modifications of existing revenue arrangements . this standard eliminates the requirement to establish the fair value of undelivered products and services and instead provides for separate revenue recognition based upon our best estimate of the selling price for an undelivered item when there is no other means to determine the fair value of that undelivered item . under our strategic alliance with mundipharma and purdue , we recognized revenues from non-refundable , up-front license fees on a straight-line basis over the contracted or estimated period of performance , which was the research and development term . we regularly considered whether events warranted a change in the estimated period of performance under an agreement . such a change would have caused us to modify the period of time over which we recognized revenue from the up-front license fee on a prospective basis and would , in turn , result in changes in our quarterly and annual results . we recognized

liquidity and capital resources we have not generated any revenue from the sale of drugs to date , and we do not expect to generate any such revenue for the next several years , if at all . we have instead relied on the proceeds from sales of equity securities , interest on investments , up-front license fees , expense reimbursement , milestones and cost sharing under our collaborations and debt to fund our operations . our available-for-sale debt securities primarily trade in liquid markets , and the average days to maturity of our portfolio , as of december 31 , 2012 , is less than six months . because our product candidates are in various stages of clinical and preclinical development and the outcome of these efforts is uncertain , we can not estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether , or when , we may achieve profitability . 56 our significant capital resources are as follows : december 31 , 2012 december 31 , 2011 ( in thousands ) cash , cash equivalents and available-for-sale securities $ 326,635 $ 115,937 working capital 311,086 88,995 replace_table_token_6_th cash flows the principal use of cash in operating activities in all periods presented was related to our research and development programs . on july 17 , 2012 , we , mundipharma , and purdue mutually agreed to terminate our strategic alliance agreements , and as a result , mundipharma discontinued all research and development funding thereafter . during the years ended december 31 , 2012 , 2011 and 2010 , we received research and development funding from mundipharma and purdue totaling $ 55 million , $ 85 million and $ 65 million , respectively .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources we have not generated any revenue from the sale of drugs to date , and we do not expect to generate any such revenue for the next several years , if at all . we have instead relied on the proceeds from sales of equity securities , interest on investments , up-front license fees , expense reimbursement , milestones and cost sharing under our collaborations and debt to fund our operations . our available-for-sale debt securities primarily trade in liquid markets , and the average days to maturity of our portfolio , as of december 31 , 2012 , is less than six months . because our product candidates are in various stages of clinical and preclinical development and the outcome of these efforts is uncertain , we can not estimate the actual amounts necessary to successfully complete the development and commercialization of our product candidates or whether , or when , we may achieve profitability . 56 our significant capital resources are as follows : december 31 , 2012 december 31 , 2011 ( in thousands ) cash , cash equivalents and available-for-sale securities $ 326,635 $ 115,937 working capital 311,086 88,995 replace_table_token_6_th cash flows the principal use of cash in operating activities in all periods presented was related to our research and development programs . on july 17 , 2012 , we , mundipharma , and purdue mutually agreed to terminate our strategic alliance agreements , and as a result , mundipharma discontinued all research and development funding thereafter . during the years ended december 31 , 2012 , 2011 and 2010 , we received research and development funding from mundipharma and purdue totaling $ 55 million , $ 85 million and $ 65 million , respectively .
```    
 Suspicious Activity Report : we completed patient enrollment in a phase 2 , randomized , double-blind , placebo-controlled clinical trial evaluating retaspimycin hcl in combination with docetaxel , a chemotherapy , compared to placebo and docetaxel in 226 patients with second- or third-line non-small cell lung cancer ( nsclc ) , who are naive to docetaxel treatment and have a history of heavy smoking . we stratified patients in our phase 2 trial by squamous cell carcinoma and adenocarcinoma based on results from our phase 1b trial in which we observed partial responses in patients with squamous cell carcinoma . in addition , we are prospectively evaluating a novel biomarker that we believe may be predictive of response . we expect to report topline overall survival data from this trial in the first half of 2013. we are also enrolling patients in a phase 1b/2 trial to explore the safety and efficacy of retaspimycin hcl in combination with everolimus , an inhibitor of the mammalian target of rapamycin ( mtor ) , pathway , in nsclc patients with a kras gene mutation . the objective of this phase 1b/2 trial is to determine the recommended dose for the combination treatment and to evaluate the safety and clinical activity of retaspimycin hcl in combination with everolimus . we expect to provide an update from this phase 1b/2 trial in the first half of 2013. in addition to our clinical stage programs , we have multiple innovative projects in earlier stages of development . through our internal discovery efforts , we also discovered ipi-940 , a novel , orally available inhibitor of faah . it is believed that inhibition of faah may enable the body to bolster its own analgesic and anti-inflammatory response , and may have applicability in a broad range of painful or inflammatory conditions . we are currently seeking potential partnering opportunities for our faah program . in june 2012 , we voluntarily stopped all company-sponsored clinical trials of saridegib , our lead hedgehog pathway inhibitor . strategic alliances millennium in july 2010 , we entered into a development and license agreement with intellikine , inc. , or intellikine , under which we obtained rights to discover , develop and commercialize pharmaceutical products targeting the delta and or gamma isoforms of pi3k , including ipi-145 . we paid intellikine a $ 13.5 million up-front license fee . the entirety of this fee was included as research and development expense in the year ended december 31 , 2010 , although $ 8.5 million of this fee was paid in january 2011. during the second half of 2011 , we paid intellikine $ 4.0 million in milestone payments associated with the initiation of two phase 1 studies of ipi-145 , which we recorded as research and development expense . in january 2012 , intellikine was acquired by takeda pharmaceutical company limited , or takeda , acting through its millennium business unit . we refer to our pi3k program licensor as millennium . in december 2012 , we amended and restated our development and license agreement with millennium . under the original agreement , we obtained worldwide development and commercialization rights to millennium 's portfolio of inhibitors of the delta and or gamma isoforms of pi3k for all indications , and we conducted a collaborative research program with millennium to identify compounds directed to pi3k-delta and or pi3k-gamma which meet certain selectivity criteria , with such research collaboration under the original agreement set to expire in july 2013. also under the original agreement , neither we nor millennium were permitted to research , develop or commercialize products directed pi3k-delta and or pi3k-gamma which meet certain selectivity criteria , other than the compounds subject to the collaboration , except that millennium was permitted to research , develop or commercialize such products that it was researching , developing or commercializing on its own or with a third party prior to its acquisition of intellikine . 45 under the terms of the amended and restated agreement , we retained our worldwide development and commercialization rights for products arising from the agreement for all therapeutic indications . we and millennium will no longer conduct the collaborative research program and the restrictions on each party 's ability to research , develop and commercialize products directed to the delta and or gamma isoforms of pi3k that meet certain selectivity criteria have terminated , subject , in the case of millennium , to the exclusive licenses granted to us under the amended and restated agreement . additionally , under the amended and restated agreement , millennium waived the option it had under the original agreement to convert , upon payment of an option fee , its royalty interest in u.s. sales of pi3k products and its right to receive certain milestone payments with respect to such products into the right to share in 50 % of profits and losses on u.s. development and commercialization of those pi3k products for which the first phase 2 clinical trial , as defined in the original agreement , was conducted in an oncology indication , and to participate in up to 30 % of the detailing effort for these products in the united states . in consideration of such waiver we have agreed to pay to millennium $ 15 million payable in installments . we have paid $ 1.7 million of the $ 15 million during the year ended december 31 , 2012. additionally , under the amended and restated agreement we have paid millennium a $ 5 million milestone payment associated with the initiation of our phase 2a clinical trial of ipi-145 in patients with mild , allergic asthma . under the terms of the original agreement , the initiation of the phase 2a trial in asthma would not have required a milestone payment . story_separator_special_tag financial overview revenue all of our revenue to date has been derived from license fees , the reimbursement of research and development costs , contract service revenue and milestone payments received from our collaboration partners . license fees were recognized as revenue ratably over the expected research and development period under our arrangement with mundipharma and purdue . because our agreements with mundipharma and purdue also provided for funding for our research and development efforts , we recognized this cost reimbursement as revenue in the period earned in proportion to our forecasted total expenses as compared to the total research funding budget for the year . in the future , we may generate revenue from a combination of product sales , research and development support services and milestone payments in connection with strategic relationships , and royalties resulting from the sales of products developed under licenses of our intellectual property . we expect that any potential future revenue we generate will fluctuate from year to year as a result of the timing and amount of license fees , research and development reimbursement , milestone and other payments earned under our collaborative or strategic relationships , and the amount and timing of payments that we earn upon the sale of our products , to the extent any are successfully commercialized . research and development expense we are a drug discovery and development company . our research and development expense primarily consists of the following : compensation of personnel associated with research activities ; clinical testing costs , including payments made to contract research organizations ; costs of purchasing laboratory supplies and materials ; costs of manufacturing product candidates for preclinical testing and clinical studies ; costs associated with the licensing of research and development programs ; preclinical testing costs , including costs of toxicology studies ; fees paid to external consultants ; fees paid to professional service providers for independent monitoring and analysis of our clinical trials ; costs for collaboration partners to perform research activities , including development milestones for which a payment is due when achieved ; depreciation of equipment ; and allocated costs of facilities . 50 general and administrative expense general and administrative expense primarily consists of compensation of personnel in executive , finance , accounting , legal , information technology infrastructure , corporate communications , corporate development , human resources and commercial functions . other costs include facilities costs not otherwise included in research and development expense , and professional fees for legal and accounting services . general and administrative expense also consists of the costs of maintaining our intellectual property portfolio . other income and expense interest and investment income typically consists of interest earned on cash , cash equivalents and available-for-sale securities , net of interest expense , and amortization of warrants . interest expense included amortization of the loan commitment asset from purdue entities , net , from april 2009 through november 2011 when we drew down the full $ 50 million loan available under the line of credit agreement . interest expense also included accrued interest on the long-term debt , including amortization of the debt discount , through september 7 , 2012 when the debt was extinguished . income from massachusetts tax incentive award represents the pro-rata amount earned for an award we received for headcount growth . critical accounting policies and significant judgments and estimates the following discussion and analysis of our financial condition and results of operations is based on our financial statements , which have been prepared in accordance with accounting principles generally accepted in the united states . the preparation of these financial statements requires us to make judgments , estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes . on an ongoing basis , we evaluate our estimates , including those related to revenue recognition , accrued expenses , and assumptions in the valuation of stock-based compensation . we base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances . actual results could differ from those estimates . differences between actual and estimated results have not been material and are adjusted in the period they become known . we believe that the following accounting policies and estimates are most critical to understanding and evaluating our reported financial results . please refer to note 2 to our consolidated financial statements for a description of our significant accounting policies . revenue recognition to date , all of our revenue has been generated under research collaboration agreements . the terms of these research collaboration agreements may include payment to us of non-refundable , up-front license fees , funding or reimbursement of research and development efforts , milestone payments if specified objectives are achieved , and or royalties on product sales . on january 1 , 2011 , we adopted on a prospective basis a newly issued accounting standard related to multiple-deliverable revenue arrangements . we apply this standard to new revenue arrangements or material modifications of existing revenue arrangements . this standard eliminates the requirement to establish the fair value of undelivered products and services and instead provides for separate revenue recognition based upon our best estimate of the selling price for an undelivered item when there is no other means to determine the fair value of that undelivered item . under our strategic alliance with mundipharma and purdue , we recognized revenues from non-refundable , up-front license fees on a straight-line basis over the contracted or estimated period of performance , which was the research and development term . we regularly considered whether events warranted a change in the estimated period of performance under an agreement . such a change would have caused us to modify the period of time over which we recognized revenue from the up-front license fee on a prospective basis and would , in turn , result in changes in our quarterly and annual results . we recognized

